Navigation Links
Protox Announces Positive Clinical Data from Prostate Cancer Study

ease in PSADT (15 of 15 patients) and a decrease in PSAV (11 of 15 patients), both of which are very positive outcomes for the patient. Results show that in 10 of 15 patients PSA levels were below baseline at 90 days or longer post-treatment. In 14 of the 15 patients, a decrease in PSA levels was observed during at least one of the, 30-, 60- or 90-day follow-up intervals.

The company expects that a final report that will include top-line PSA data with expanded analysis of PSADT and PSAV will be available for release in October. Plans are underway to commence a Phase 2 study before the end of the year.

Conference call

Protox will host a conference call and live webcast today at 12:00 p.m. E.T. to discuss these results. To access the conference call by telephone, dial 416-644-3414 or 1-800-732-9307. Please connect approximately ten minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until August 10, 2007 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21240373 followed by the number sign. A live audio webcast of the conference call will be available at http://www.protoxtherapeutics.com. Please connect at least ten minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 30 days.

About Protox

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), and currently has four programs in clinical
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:4/28/2015)... 28, 2015 Recent Highlights: ... first patient in PerClot ® IDE ... device and tissue processing company focused on cardiac and ... quarter of 2015.  Pat Mackin, Chairman, ... significant milestones regarding two of our top organizational objectives.  ...
(Date:4/28/2015)... BERLIN , April 28, 2015 ... universities of Berlin and the ... Berlin as a central research location ... of scientific, technical and medical information products and services, ... Charité, the Humboldt University (Humboldt-Universität), the Free University ...
(Date:4/28/2015)... 28, 2015  Influential proxy advisory firm Institutional ... at Gilead Sciences, a shareholder proposal asking the ... management and mitigation of the business risks associated ... of rapidly increasing U.S. drug prices and efforts ... costs. Proposal 8, Stockholder ...
Breaking Medicine Technology:CryoLife Reports First Quarter Results 2CryoLife Reports First Quarter Results 3CryoLife Reports First Quarter Results 4CryoLife Reports First Quarter Results 5CryoLife Reports First Quarter Results 6CryoLife Reports First Quarter Results 7CryoLife Reports First Quarter Results 8CryoLife Reports First Quarter Results 9Elsevier and the Friedrich-Althoff Consortium Collaborate to Create "Archive of Berlin" as a Basis for a Common Research Infrastructure 2Elsevier and the Friedrich-Althoff Consortium Collaborate to Create "Archive of Berlin" as a Basis for a Common Research Infrastructure 3ISS Recommends Shareholders Vote For Specialty Drug Pricing Risk Assessment Proposal At Gilead Sciences 2ISS Recommends Shareholders Vote For Specialty Drug Pricing Risk Assessment Proposal At Gilead Sciences 3
(Date:4/28/2015)... 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... accounted for 3,822 of the pharmaceutical and 1,998 of ...
(Date:4/28/2015)... 2015 An Allegheny Health Network ... MD, FACS , has launched the first U.S. clinical ... matrix (ECM) can help patients who are at high ... , ECM is a complex mixture of naturally-occurring polymers ... and signals that guide cell behavior. ECM, manufactured from ...
(Date:4/28/2015)... Culver City, CA (PRWEB) April 28, 2015 ... today in the Journal of Molecular Imaging and ... with [18F]DCFPyL, a 2nd generation fluorine-18 labeled small-molecule ... at Johns Hopkins University in Baltimore, MD by ... , “This initial human evaluation of [18F]DCFPyL demonstrated ...
(Date:4/28/2015)... April 28, 2015 The buyer power ... out of 5, indicating a medium level of buyer ... and suppliers have equal power during negotiations. One factor ... than purchasing a health insurance policy from an insurance ... Humana), buyers can choose to self-fund their own policy ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Wimbledon ... which provides vascular, electrocardiogram, echocardiogram, and NCV testing, ... vascular testing to help podiatrists diagnose peripheral arterial ... to diagnose PAD without the aid of vascular ... Medical Officer at Wimbledon Health Partners. “Diminished ...
Breaking Medicine News(10 mins):Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:Podiatrists Affiliate with Wimbledon Health Partners to Diagnose Peripheral Arterial Disease 2
... to Laurus Fully Repaid, LARGO, Fla., Oct. ... DYHP.OB) ("Dynamic"), a leading distributor in,the sports nutrition ... filed its Articles of Merger with the Florida ... of its merger with GeoPharma, Inc.,(Nasdaq: GORX ...
... Oct. 15 Speaker Nancy Pelosi,issued the following ... override,President Bush,s veto of the State Children,s Health ... in the House who have not already joined,this ... their vote,and to stand with 10 million children ...
... MINNEAPOLIS, Oct. 15 The Health Care,Compliance Association ... important compliance concerns for hospitals and for physicians,outlined ... Services Office of,Inspector General (OIG) 2008 Work Plan. ... industry., This vital two-part audio/web conference will ...
... Also Renews Commitment to Darfur, STAMFORD, Conn., Oct. ... more than $7,billion in aid to people in need ... AmeriCares President and CEO Curt Welling announced the milestone ... held at Westchester County Airport on Saturday., "I ...
... addition to Masimo Rainbow SET platform seen as having,potential clinical ... ... FRANCISCO, Oct. 15 Masimo, the inventor,of Pulse CO-Oximetry and ... independent and objective clinical study,presented today at the 2007 American ...
... of motion, study found , MONDAY, Oct. 15 ... and after surgery, helped reduce pain and promote mobility ... finding was presented Sunday at the annual meeting of ... The study, funded by drug maker Pfizer Inc., included ...
Cached Medicine News:Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 3Health News:Critical HCCA Web/Audio Conference Will Review Office of Inspector General Compliance Concerns Outlined in FY 2008 Work Plan 2Health News:AmeriCares Passes $7 Billion Mark in Aid Distributed 2Health News:Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume 2Health News:Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume 3Health News:Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume 4Health News:Anti-Convulsant Aids Knee-Replacement Patients 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: